Universities and research institutes at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

149 universities and research institutes are at ESMO 2026 — 345 presentations on the program. Most represented: Medical University of Vienna (11 on the program), University College London (8 on the program), University of Turin (6 on the program). 48 of them have their own page in this guide. As of Sep 29, 2026.

All 736 organizations at ESMO 2026 →

Showing 1–3 of 149 organizations

Organization	ESMO 2026 Attendance
Medical University of Vienna Vienna, Austria
meduniwien.ac.at University & institute Public medical university in Vienna, Austria, whose clinical departments are based at Vienna General Hospital.	Talk Fri Oct 23 13:30–13:50 How to select the optimal adjuvant therapy Update on the mangement of endometrial cancer in the era of molecular classification Gynaecological cancers Chair Fri Oct 23 13:30–15:00 Update on the mangement of endometrial cancer in the era of molecular classification with European Institute of Oncology (IEO) Gynaecological cancers Abstract Fri Oct 23 13:35–13:40 696RO - Non-invasive finger sweat-based response monitoring of vorasidenib treatment in patients with IDH-mutant glioma Rapid oral: CNS tumours Sarcoma, CNS, head & neck and rare cancers Abstract Fri Oct 23 14:37–14:42 703RO - Inflammatory and epigenetic signatures in progressive brain metastases after cranial radiotherapy Rapid oral: CNS tumours Sarcoma, CNS, head & neck and rare cancers Keynote Fri Oct 23 15:15–15:20 Introduction Keynote lecture 1 Sarcoma, CNS, head & neck and rare cancers Chair Fri Oct 23 15:15–15:45 Keynote lecture 1 Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 08:50–09:10 Immune niche development and metastases Metastases: Understanding and targeting cancer spread Biomarkers & precision oncology Satellite Sat Oct 24 13:00–13:10 Overview GI Cancers: Translating Innovation into Practice and Better Patient Care Servier - GI Oncology in Motion : Real-World Cases and Patient Centric Care Gastrointestinal cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Servier - GI Oncology in Motion : Real-World Cases and Patient Centric Care with Hospital Universitario Fundación Jiménez Díaz Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 09:00–10:00 YO Clinical case discussions with Aga Khan University Hospital Abstract Sun Oct 25 09:42–09:52 Invited Discussant 3588O and 3592O Proffered paper 2: Genitourinary tumours, renal and urothelial Genitourinary cancers Abstract Sun Oct 25 10:15–10:25 690O - Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD) Proffered paper: CNS tumours Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 10:15–11:45 Proffered paper: CNS tumours with IRCCS Istituto delle Scienze Neurologiche di Bologna Sarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 10:15–11:45 Tumour systemic immunity with Institute of Oncology Research (IOR) Chair Sun Oct 25 10:30–11:15 YO Brunch 2 with Krankenhaus Nordwest Chair Sun Oct 25 14:45–16:15 Key challenges in managing patients with metastatic breast cancer with Hospital Universitario 12 de Octubre Breast cancer Chair Mon Oct 26 14:45–16:00 Modern management of leptomeningeal metastases with Maastricht UMC+ Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 14:45–16:15 Rapid oral: Prevention, early detection and intervention with Netherlands Cancer Institute, MD Anderson Cancer Center Talk Mon Oct 26 15:10–15:30 Systemic therapies for leptomenigeal disease Modern management of leptomeningeal metastases Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 15:27–15:39 Invited Discussant 3884RO, 1150RO and 1151RO Rapid oral: Prevention, early detection and intervention
University College London London, United Kingdom
ucl.ac.uk University & institute Public research university in London, England, with a medical school and a cancer institute.	Chair Fri Oct 23 13:30–15:00 Key biological concepts and their clinical implication with National Autonomous University of Mexico Biomarkers & precision oncology Talk Fri Oct 23 14:10–14:30 Cancer cell plasticity and cancer evolution Key biological concepts and their clinical implication Biomarkers & precision oncology Abstract Sat Oct 24 11:10–11:20 2045O - Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically very high risk prostate cancer (PCa) Proffered paper: Genitourinary tumours, prostate, penile and testils Genitourinary cancers Chair Sat Oct 24 14:45–16:00 Management of locally advanced HCC with Hospital Universitario Fundación Jiménez Díaz Gastrointestinal cancers Talk Sat Oct 24 14:50–15:05 View of the medical oncologist: Integration of systemic therapies with locoregional therapy Management of locally advanced HCC Gastrointestinal cancers Talk Sun Oct 25 11:15–11:30 Advanced/metastatic prostate cancer: Discussion ESMO Clinical Practice Guidelines 2 Breast cancerGenitourinary cancers Chair Sun Oct 25 14:45–16:15 Proffered paper 1: Basic science and translational research with Institute of Oncology Research (IOR) Abstract Sun Oct 25 14:50–14:55 3590RO - Patient reported outcomes in resected renal cell carcinoma: adjuvant durvalumab versus active monitoring in the RAMPART trial Rapid oral 2: Genitourinary tumours, renal and urothelial Genitourinary cancers Abstract Sun Oct 25 15:05–15:15 4237O - Radiological tracking of metastatic growth and its molecular correlates in lung cancer Proffered paper 1: Basic science and translational research Abstract Sun Oct 25 15:57–16:07 Invited Discussant 4238O and 4239O Proffered paper 1: Basic science and translational research Chair Mon Oct 26 12:15–12:45 Keynote lecture 4 Abstract Mon Oct 26 15:05–15:17 Invited Discussant 4240O, 4241O and 4242O Proffered paper 2: Basic science and translation research Biomarkers & precision oncology
University of Turin Turin, Italy
unito.it University & institute Public university in Turin, Italy, with a school of medicine and a molecular biotechnology research centre.	Abstract Fri Oct 23 13:30–13:35 695RO - Early predictors of vorasidenib efficacy in IDH-mutant grade 2 glioma: a prospective study integrating volumetric MRI, amino acid PET, plasma D-2- hydroxyglutarate, and seizure outcome Rapid oral: CNS tumours Sarcoma, CNS, head & neck and rare cancers Chair Sat Oct 24 08:30–10:00 Proffered Paper: Haematological malignancies with Institute of Oncology Research (IOR) Haematological malignancies Chair Sat Oct 24 12:00–12:50 ESMO-EACR: What oncologists should know about molecular oncology with Gustave Roussy, VIB Biomarkers & precision oncology Talk Sat Oct 24 12:00–12:15 RAS biology ESMO-EACR: What oncologists should know about molecular oncology Biomarkers & precision oncology Satellite Sat Oct 24 18:30–18:45 At a pivotal time: Where we stand today PharmaMar - More time for patients: Reframing the course of ES-SCLC Lung & thoracic cancers Satellite Sat Oct 24 18:30–20:00 PharmaMar - More time for patients: Reframing the course of ES-SCLC Lung & thoracic cancers Talk Sun Oct 25 08:50–09:10 Novel approaches challenging the role of transplantation in the treatment of front-line myeloma Changing paradigms in lymphomas and myeloma Haematological malignancies Satellite Sun Oct 25 13:00–14:30 BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:From Early-Stage Immunotherapy to New Modalities in Advanced Disease with Hospital Universitario Puerta de Hierro Majadahonda Lung & thoracic cancers Satellite Sun Oct 25 13:00–13:05 Welcome and Introductions BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with Hospital Universitario Puerta de Hierro Majadahonda Lung & thoracic cancers Satellite Sun Oct 25 13:20–14:05 Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with University Hospital Cologne, Trinity St James's Cancer Institute, Hospital Universitario Puerta de Hierro Majadahonda +1 more Lung & thoracic cancers Satellite Sun Oct 25 14:25–14:30 Close BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with Hospital Universitario Puerta de Hierro Majadahonda Lung & thoracic cancers Chair Mon Oct 26 08:30–10:00 Navigating cellular aging: Optimising cancer therapy in the aging population with Institute for Research in Biomedicine (IRB Barcelona) Talk Mon Oct 26 08:55–09:20 The immunotherapy challenge in aging: From MSS to MSI Navigating cellular aging: Optimising cancer therapy in the aging population Abstract Mon Oct 26 09:02–09:07 3721RO - Quantitative PARP1 H-score as a predictive biomarker for trabectedin plus olaparib combination in advanced soft tissue sarcoma: exploratory analysis of the TOMAS2 study Rapid oral: Sarcoma Sarcoma, CNS, head & neck and rare cancers